Open AccessPhase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
Author(s) -
Maria Rovithi,
Sophie L. Gerritse,
Richard J. Honeywell,
Albert J. ten Tije,
Rita Ruijter,
Godefridus J. Peters,
Jens Voortman,
Mariëtte Labots,
Henk M.W. Verheul
Publication year - 2019
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.18.00725
Subject(s) - medicine , tolerability , adverse effect , nausea , refractory (planetary science) , sunitinib , dosing , regimen , surgery , cancer , gastroenterology , physics , astrobiology
Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost importance. On the basis of preclinical data, a phase I clinical trial of once weekly or once every 2 weeks administration of high-dose sunitinib in patients with refractory solid malignancies was conducted.